Towards Understanding the Health and Economic Impacts of Quadrivalent and Trivalent Inactivated Vaccines Against Influenza B Infection: Additional Considerations for Future Cost-Benefit Analyses

Affiliations

¹ Department of Basic and Clinical Sciences, Albany College of Pharmacy and Health Sciences, Albany, New York, USA.
² Department of Population Health Sciences, Albany College of Pharmacy and Health Sciences, Albany, New York, USA.

Comment

Eric J Yager et al. Clin Infect Dis. 2020.

. 2020 Dec 15;71(12):3263-3264.

doi: 10.1093/cid/ciaa309.

¹ Department of Basic and Clinical Sciences, Albany College of Pharmacy and Health Sciences, Albany, New York, USA.
² Department of Population Health Sciences, Albany College of Pharmacy and Health Sciences, Albany, New York, USA.

No abstract available

Comment in

Reply to Yager and Doll.
Gaglani M, Flannery B. Gaglani M, et al. Clin Infect Dis. 2020 Dec 15;71(12):3264-3265. doi: 10.1093/cid/ciaa311. Clin Infect Dis. 2020. PMID: 32202294 No abstract available.

Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011-2012 to 2016-2017.
Gaglani M, Vasudevan A, Raiyani C, Murthy K, Chen W, Reis M, Belongia EA, McLean HQ, Jackson ML, Jackson LA, Zimmerman RK, Nowalk MP, Monto AS, Martin ET, Chung JR, Spencer S, Fry AM, Flannery B. Gaglani M, et al. Clin Infect Dis. 2021 Apr 8;72(7):1147-1157. doi: 10.1093/cid/ciaa102. Clin Infect Dis. 2021. PMID: 32006430 Free PMC article.